A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2023-04-05
Adverse events
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-04-23 (study day 12); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-04-25 (study day 14); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-30 (study day 19); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-05-02 (study day 21); relationship: not assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-05-09 (study day 28); relationship: not assessed
Data queries
No data queries.